Anti-βGal-hCD3
-
Cat.code:
bimab-bgcd3-01
- Documents
The cat. codes have been changed from bimab-bgalhcd3 and bimab-bgalhcd3-05 to bimab-bgcd3-01 and bimab-bgcd3-05.
ABOUT
Monoclonal scFv antibody against β-galactosidase and human CD3 - Negative control
Anti-βGal-hCD3 is a bispecific antibody that binds to two sites: E. coli β-galactosidase (β-Gal)and hCD3, part of the T cell receptor. It is used as a negative control for Anti-hCD19-CD3 bispecific antibody that, alike Blinatumomab, engages unstimulated T cells to proliferate and exert cytotoxic activity on CD19-positive lymphoma cells [1,2].
References:
1. Krishnamurthy A. & Jimeno A., 2017. Bispecific antibodies for cancer therapy: A review. Pharmacol Ther. S0163-7258(17)30293-0.
2. Bargou R. et al., 2008. Tumor Regression in Cancer Patients by Very Low Doses of a T Cell– Engaging Antibody. Science. 321(5891):974-7.
Illustration on this page were created with BioRender.com.
All products are for research use only, and not for human or veterinary use.
SPECIFICATIONS
Specifications
CD3, β-Galactosidase
Human, E. coli
Negative control antibody
Sodium phosphate buffer, saccharose
Negative (tested using EndotoxDetect™ assay)
Cellular assays, ELISA, flow cytometry
Each lot is validated by flow cytometry.
CONTENTS
Contents
-
Product:Anti-βGal-hCD3
-
Cat code:bimab-bgcd3-01
-
Quantity:10 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
Powered by Bioz
